Director Chemistry-Biochemistry-Biology Interface (CBBI) Program
Mayland Chang is Research Professor in the Department of Chemistry and Biochemistry at the University of Notre Dame, Program Director of the Chemistry-Biochemistry-Biology Interface (CBBI) Program, and Founding Member of Nupromed, a start-up company focused on the development of effective and innovative pharmaceuticals for unmet medical needs. Her research focuses on understanding of the molecular basis of neurological diseases, the development of new antibiotics, and using pharmacokinetics and pharmacodynamics as an integral approach to drug design and lead optimization. She brings 25 years of experience in drug discovery and development, and clinical trials management.
Prior to joining the University of Notre Dame, Dr. Chang was Chief Operating Officer of University Research Network, Inc., where she established an academic research organization for Wayne State University School of Medicine that facilitated clinical research and provided clinical development services to the pharmaceutical and biotechnology industries. Previously, Dr. Chang was Senior Scientist with Pharmacia Corporation (Pfizer, Inc. as of 2003), and Senior Chemist at Dow Chemical Company. During her industrial career, Dr. Chang has seen three of her projects brought to commercialization. Dr. Chang holds bachelor degrees in biology and chemistry from the University of Southern California, a Ph.D. degree in chemistry from The University of Chicago, and was an NIH Postdoctoral Fellow at Columbia University.